Patients homozygous for the CD16A valine variant (CD16A-V/V) had an improved clinical outcome after treatment with anti-tumor mAbs compared to those who were either heterozygous (CD16A-V/F) or homozygous (CD16A-F/F) for the lower affinity FcγRIIIA isoform [as reviewed in Wang et al. (4)]. This evidence concerns the gene FCGR3A and neoplasm.